Eli Lilly Challenges Custom Tirzepatide–But This Healthtech Startup Is Fighting Back
Eli Lilly (NYSE:LLY) just pre-announced a $1.57 billion pre-tax charge related to acquired in-process R&D, which is expected to weigh…
Eli Lilly (NYSE:LLY) just pre-announced a $1.57 billion pre-tax charge related to acquired in-process R&D, which is expected to weigh…